Solventum Corporation (NYSE:SOLV) Receives Consensus Rating of "Hold" from Brokerages

Key Points

• Solventum has a consensus “Hold” rating from 13 brokerages, with seven buys, five holds and one sell. The average 12-month price target is $91.64, above the reported opening price of $83.00.
• Q2 results exceeded expectations: adjusted EPS was $2.55 versus the $1.91 consensus, while revenue reached $2.21 billion and organic sales grew 9.5% year over year.
• Management raised fiscal 2026 EPS guidance to $7.10–$7.20, while several analysts increased their price targets. The planned separation of Solventum’s health information systems business could further focus operations and unlock shareholder value.

Solventum Corporation (NYSE:SOLV - Get Free Report) has been given an average recommendation of "Hold" by the thirteen research firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and seven have given a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $91.6364.

A number of brokerages have recently issued reports on SOLV. Wedbush upped their price objective on shares of Solventum from $94.00 to $101.00 and gave the company an "outperform" rating in a research note on Thursday. Wall Street Zen upgraded shares of Solventum from a "hold" rating to a "buy" rating in a research report on Saturday. Weiss Ratings upgraded shares of Solventum from a "hold (c)" rating to a "hold (c+)" rating in a research report on Friday, July 17th. Wells Fargo & Company reduced their price objective on Solventum from $83.00 to $70.00 and set an "equal weight" rating on the stock in a research note on Wednesday, May 6th. Finally, Mizuho set a $113.00 price objective on Solventum in a report on Thursday.

Hedge Funds Weigh In On Solventum

Several institutional investors and hedge funds have recently bought and sold shares of SOLV. Trust Co. of Vermont purchased a new position in Solventum in the 2nd quarter worth approximately $119,000. Hikari Power Ltd purchased a new stake in shares of Solventum during the second quarter valued at approximately $362,000. Diamond Hill Capital Management LLC Investment Advisor purchased a new stake in shares of Solventum during the second quarter valued at approximately $150,066,000. Bank of New York Mellon Corp bought a new position in shares of Solventum in the second quarter worth approximately $61,460,000. Finally, Stoneridge Investment Partners LLC bought a new position in shares of Solventum in the second quarter worth approximately $689,000.

Key Solventum News

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Q2 results exceeded expectations. Solventum reported adjusted earnings of $2.55 per share versus the $1.91 consensus estimate, while revenue of $2.21 billion also topped forecasts. Organic sales increased 9.5%, and revenue grew 2.2% year over year. Solventum Stock Up as Q2 Earnings & Revenues Beat Estimates
• Positive Sentiment: Management raised 2026 earnings guidance to $7.10-$7.20 per share, above its previous outlook. Strong cash flow and the company’s share-repurchase activity further support investor sentiment, although some of the quarter’s benefit came from ERP implementation timing. Solventum outlines HIS separation and raises 2026 EPS guide
• Positive Sentiment: Analyst conviction strengthened. Piper Sandler raised its target to $105 and maintained an overweight rating; Wedbush lifted its target to $101 with an outperform rating; and Stifel increased its target to $100 with a buy rating. UBS also reiterated its buy recommendation. UBS Remains a Buy on Solventum Corporation
• Positive Sentiment: Software separation could sharpen the company’s focus. Solventum plans to separate its health information systems business, potentially creating a more focused medical-technology company and unlocking value from the remaining operations. Solventum to hive off healthcare software business

Solventum Stock Performance

NYSE:SOLV opened at $83.00 on Friday. The company has a market capitalization of $14.13 billion, a price-to-earnings ratio of 10.15, a PEG ratio of 1.18 and a beta of 0.60. The business has a 50 day moving average of $79.40 and a 200 day moving average of $74.44. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.02 and a quick ratio of 0.75. Solventum has a 1-year low of $62.38 and a 1-year high of $90.00.

Solventum (NYSE:SOLV - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $2.55 EPS for the quarter, beating analysts' consensus estimates of $1.91 by $0.64. The business had revenue of $2.21 billion for the quarter, compared to analysts' expectations of $2.15 billion. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The business's quarterly revenue was up 2.2% on a year-over-year basis. During the same period last year, the business earned $1.69 earnings per share. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. On average, sell-side analysts predict that Solventum will post 7.15 earnings per share for the current fiscal year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source